BlackBarn Capital Partners LP: ROIVANT SCIENCES LTD (ROIV): Quarterly 13F Position History
As of Q2 2026, BlackBarn Capital Partners LP reported 2,000,000 shares of ROIVANT SCIENCES LTD (ROIV), worth $70.8M and representing 17.6% of its 13F equity book. Quarter-over-quarter share count change: 285,117 (-12.5%) . The position first appeared in Q4 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 2,000,000Shares Held (Latest Filing)
- $70.8MReported Market Value (Latest Filing)
- 17.6%Portfolio Weight (% of 13F Equity Book)
- 285,117Quarter-over-Quarter Share Change
- +$7.5MQuarter-over-Quarter Value Change
- 4,750,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,000,000 | 285,117 | -12.5% | $70.8M | 17.6% | $35.4 |
| Q1 2026 | 2,285,117 | 799,183 | -25.9% | $63.3M | 19.0% | $27.7 |
| Q4 2025 | 3,084,300 | 1,315,700 | -29.9% | $66.9M | 24.0% | $21.7 |
| Q3 2025 | 4,400,000 | 225,000 | -4.9% | $66.6M | 21.7% | $15.1 |
| Q2 2025 | 4,625,000 | 125,000 | -2.6% | $52.1M | 17.3% | $11.3 |
| Q1 2025 | 4,750,000 | +625,000 | +15.2% | $47.9M | 16.4% | $10.1 |
| Q4 2024 | 4,125,000 | +125,000 | +3.1% | $48.8M | 19.2% | $11.8 |
| Q3 2024 | 4,000,000 | +900,000 | +29.0% | $46.2M | 20.1% | $11.5 |
| Q2 2024 | 3,100,000 | +1,199,406 | +63.1% | $32.8M | 16.9% | $10.6 |
| Q1 2024 | 1,900,594 | +350,594 | +22.6% | $20.0M | 11.6% | $10.5 |
| Q4 2023 | 1,550,000 | – | – | $17.4M | 11.5% | $11.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did BlackBarn Capital Partners LP first disclose a ROIV position in 13F-HR filings?
BlackBarn Capital Partners LP first reported ROIVANT SCIENCES LTD (ROIV) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was BlackBarn Capital Partners LP's most recent quarter-over-quarter share-count change in ROIV?
Between Q1 2026 and Q2 2026, BlackBarn Capital Partners LP reduced its ROIV position by 285,117 shares (-12.5%), leaving 2,000,000 shares at a market value of $70.8M.
Does the implied price-per-share represent BlackBarn Capital Partners LP's cost basis in ROIV?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.